Dr. Reddy's Laboratories

It is estimated that approximately 212 million people in India live with diabetes, and of them, around 133 million are not on medication. Undiagnosed or untreated diabetes can damage blood vessels and nerves that control the heart, lead to hypertension or dyslipidemia, thereby increasing the risk of severe cardiovascular disease. The observance of #WorldDiabetesDay is a call to all of us to test regularly for diabetes, and to monitor our blood sugar levels. Our promise to help patients manage disease better in the diabetes and cardiovascular therapy area has continued strongly in India for over three decades, led by our trusted and growing portfolio of market-leading products – for diabetes, hypertension, heart failure. Our patient support programmes in the therapy area offer early screening for diabetes and related complications, as well as holistic health support beyond medication, altogether reaching hundreds of thousands of patients in India. Each product and service is a contribution towards tackling the formidable disease burden, and towards our aim to serve over 1.5 billion patients by 2030. #GoodHealthCantWait #WeAreDrReddys #Beyond100

The story of how our market-leading anti-diabetes products, Reclide (Gliclazide) and Reclimet (Gliclazide + Metformin), were born in India in the 1990s - A passing conversation with a friend in the 1990s sparked our Founder Dr. Anji Reddy’s concern for the affordability and reach of the most effective diabetes drug of the day in India. This led Dr. Reddy to manufacture and market two top anti-diabetes drugs at affordable prices – leading to the birth of Reclide and Reclimet. On #WorldDiabetesDay, we re-play a story that stands as testament to our commitment to making innovative drugs accessible and affordable to patients, right from our early days. We remain resolute in our commitment to pursue our purpose, and to bring best-in-class drugs in the diabetes and chronic therapy area to patients. #GoodHealthCantWait #WeAreDrReddys

As part of our #WorldDiabetesDay initiatives, our Emerging Markets team has brought together eminent endocrinologists and experts from around the world for a knowledge-sharing webinar event on ‘Standard of Care and Evolution from Glucocentric to Holistic Cardio-Renal-Metabolic Approach in Modern Day Type 2 Diabetes Management’. Type 2 Diabetes to be a massive global health challenge. We hope such conversations will enable exchange of ideas, explore innovative healthcare solutions, and eventually help patients manage their health conditions better. The webinar is now LIVE, and open to healthcare professionals who may register here: https://lnkd.in/dTkxWUUi. #GoodHealthCantWait #WeAreDrReddys

India is a key focus market for us. Our CFO, M V Narasimham, describes our multi-pronged growth strategy for India including growing the big brands, adding layers of innovation (access to novel molecules, digital therapeutics, consumer healthcare), strategic collaborations, and suitable inorganic opportunities. In recent months, we have entered into collaborations with Sanofi in India for their vaccines, Bayer in India for a best-in-class product for heart failure, launched a drug-free migraine management device, and an app for an integrated approach to management of Irritable Bowel Syndrome (IBS). Our joint venture with Nestlé India, to take health science nutraceutical products to consumers in India, went live in August. For more, please see https://lnkd.in/gT6v3FrK. #GoodHealthCantWait #WeAreDrReddys

Q2 FY’25 was a good quarter for us overall – healthy revenue and good growth in all our markets. Profit After Tax (PAT) was affected by one-offs related to Nicotinell acquisition costs, the JV minority interest, changes in land tax laws, etc. Two important moves in the quarter – closure of our deal to acquire the market-leading global brand Nicotinell and the related portfolio as part of our global consumer health business, and operationalisation of our Joint Venture with Nestlé India to take science-based nutraceutical products to consumers in India. Both moves are aimed at meeting unmet consumer needs. Watch our CEO, Erez Israeli, on these topics in this interview: https://lnkd.in/deJcBBpB   #WeAreDrReddys #GoodHealthCantWait

Our post-results Q2 global townhall was an exciting mix of celebration of key achievements, taking stock of our priorities ahead, inspiring stories from colleagues, and learning about our work in sustainability and supporting women returning to the workforce. Our CEO, Erez Israeli, described highlights of what was a good quarter with key developments - closure of our acquisition of Nicotinell and related brands as part of our global consumer health focus, operationalisation of our joint venture with Nestlé India, continued progress on key products, and strategic collaborations. We recently received a non-exclusive Voluntary Licence from Gilead Sciences for the anti-retroviral drug, Lenacapavir. Our CEO - API & Services, Deepak Sapra, spoke about its potential to eliminate the threat of HIV, and our aim to expand access to this novel drug in countries with high disease burden. Our success as a partner of choice for this drug was based on our capabilities in science and manufacturing, and our commitment to providing access to innovative drugs. We currently serve over 700 million patients around the world and aim to reach over 1.5 billion patients by 2030. Our Co-Chairman and MD, Prasad G V highlighted and celebrated achievements that speak to our core tenets – recent wins in the marketplace that made a difference to patients, demonstrated our capabilities in deep science, and delivered meaningful growth. He also spoke about continued effort to shape our culture to enables such wins, including continuous learning and improvement. The townhall closed on an inspiring note - our colleague, Obiageri Amaechi, associate product manager based in our New Jersey office described her experience representing Nigeria in Women’s Discus Throw at the 2024 Paris Olympics! We are proud and inspired by Obi’s journey, and her passion in equal measure for sporting excellence and access to healthcare. We also heard from Mark Jones, one of the newest members of the Dr. Reddy’s family and Head of Supply Chain for the recently-acquired Nicotinell business as part of global consumer health. Mark described his recent participation in the ICLA 2024 European Sailing Championships in Portugal, proudly donning the Dr. Reddy’s ‘Good Health Can’t Wait’ shirt through the event! What's more, having acquired trusted vaccine brands from Sanofi India recently, we also conducted a health camp offering to administer the flu vaccine to our colleagues and their family members. Indeed, a highly motivating note to recharge us physically and emotionally for H2 FY’25! #WeAreDrReddys #GoodHealthCantWait

Join us at CPHI India 2024 at booth RH E02, where our experts will showcase how we streamline API manufacturing and supply, ensuring consistency, efficiency, and scalability. Whether you need tailored APIs for your formulations or a dependable supplier for your global production processes, we’re here to support your growth. Let’s discuss how we can meet your unique API sourcing needs and drive your success. Book a meeting and start your journey with the leaders in API manufacturing: https://rb.gy/bxhhs4 #DrReddys #DrReddysXSustainability #GoodHealthCantWait #WeAreDrReddys #DrReddysAPI #ESG #Sustainability #APIPartner #Pharmaceutical #CPHI #CPHI2024 #CPHIIndia

🌟 Did You Know? 🌟 The Human Genome Project, completed in 2003, was a landmark achievement in genomics. It successfully mapped all the genes in the human genome, providing a comprehensive blueprint of human DNA. This monumental project has paved the way for advances in personalized medicine, allowing for treatments and therapies tailored to an individual’s genetic makeup, thereby improving efficacy and outcomes in healthcare. At Aurigene, we are committed to leveraging such groundbreaking discoveries to drive innovation and enhance our capabilities in drug development. Join us in celebrating the strides made in innovative healthcare that have made a profound impact on the life as we know it! #HumanGenomeProject #PersonalizedMedicine #HealthcareInnovation #Aurigene

Today we announced our Q2 FY'25 financial results. Click here to read more: https://shorturl.at/kk8cr #WeAreDrReddys #GoodHealthCantWait

Wondering how to satisfy those post-Diwali sweet cravings without triggering your IBS? Our Head of Digital Therapeutics Dr. Jitesh Bhatt has IBS-friendly low FODMAP recipes for you! See the comments below for the ingredients and step-by-step recipe! DailyBloom IBS is a platform that helps you take an integrated approach in the management of Irritable Bowel Syndrome (IBS) – combining education, lifestyle choices, personalised nutrition and wellness. Leveraging our decades of expertise in the gastrointestinal therapy area, we aim to enhance standard of care through this offering. Visit http://dailybloomibs.com/ to learn more and download the app! #GoodHealthCantWait #WeAreDrReddys #GutHealth #IBS